Results 41 to 50 of about 516,619 (288)
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
Nature Communications, 2020 Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl +12 more
doaj +1 more source
Advanced Science, EarlyView.In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao +6 more
wiley +1 more source
A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control
Advanced Science, EarlyView.Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias +23 more
wiley +1 more source
Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids
Angewandte Chemie, EarlyView.Genetic code expansion (GCE) enables site‐specific installation of noncanonical amino acids containing bioorthogonal conjugation handles, allowing precise, homogeneous protein modification. This review examines the principles of orthogonal translation, surveys the chemistries available for chemoselective labeling, and highlights emerging multi‐site ...
Rahul Sarkar +2 more
wiley +2 more sources
STAR Protocols, 2022 Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li +8 more
doaj +1 more source
Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma
Advanced Science, EarlyView.This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert +8 more
wiley +1 more source
[Bispecific antibodies: what future?]
, 2009 International audienceMonoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR ...
Bruno Robert +3 more
core +1 more source
The emergence of bispecific antibodies as novel cancer therapeutics [PDF]
, 2023 Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new
Li, Robert
core +1 more source
Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds
Antibodies, 2018 Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs).
Lilach Vaks +9 more
doaj +1 more source